327 related articles for article (PubMed ID: 18084873)
1. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
Ushiroyama T; Ikeda A; Ueki M
J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873
[TBL] [Abstract][Full Text] [Related]
2. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
Kiev A; Feiger A
J Clin Psychiatry; 1997 Apr; 58(4):146-52. PubMed ID: 9164424
[TBL] [Abstract][Full Text] [Related]
3. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
Stahl SM; Entsuah R; Rudolph RL
Biol Psychiatry; 2002 Dec; 52(12):1166-74. PubMed ID: 12488062
[TBL] [Abstract][Full Text] [Related]
5. A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
Rapaport M; Coccaro E; Sheline Y; Perse T; Holland P; Fabre L; Bradford D
J Clin Psychopharmacol; 1996 Oct; 16(5):373-8. PubMed ID: 8889909
[TBL] [Abstract][Full Text] [Related]
6. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
Fabre L; Birkhimer LJ; Zaborny BA; Wong LF; Kapik BM
Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
8. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
[TBL] [Abstract][Full Text] [Related]
9. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
10. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Mundo E; Bianchi L; Bellodi L
J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
[TBL] [Abstract][Full Text] [Related]
12. Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine.
Chiu HJ; Hong CJ; Chan CH
Zhonghua Yi Xue Za Zhi (Taipei); 1996 Jun; 57(6):418-23. PubMed ID: 8803304
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
[TBL] [Abstract][Full Text] [Related]
14. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
Cusin C; Serretti A; Zanardi R; Lattuada E; Rossini D; Lilli R; Lorenzi C; Smeraldi E
Int J Neuropsychopharmacol; 2002 Mar; 5(1):27-35. PubMed ID: 12057029
[TBL] [Abstract][Full Text] [Related]
15. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
[TBL] [Abstract][Full Text] [Related]
16. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
Grimsley SR; Jann MW
Clin Pharm; 1992 Nov; 11(11):930-57. PubMed ID: 1464219
[TBL] [Abstract][Full Text] [Related]
17. Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?
Kertzman S; Vainder M; Reznik I; Gotzlav Y; Weizman A; Kotler M; Iancu I
Int Clin Psychopharmacol; 2012 May; 27(3):134-41. PubMed ID: 22415223
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
Haffmans PM; Timmerman L; Hoogduin CA
Int Clin Psychopharmacol; 1996 Sep; 11(3):157-64. PubMed ID: 8923094
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
[TBL] [Abstract][Full Text] [Related]
20. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
